🚀 Outstanding news from one of our earliest investments Immatics! We're thrilled to see groundbreaking advances in cancer treatment through the latest results and a robust financial positon. 🔵 Objective Response Rate: 55% confirmed responses across patients – showcasing significant tumor control. 🔵 Tumor Shrinkage: Achieved in 87% of patients, highlighting the effectiveness of our treatment. 🔵 Duration of Response: Median of 13.5 months, with responses still ongoing, demonstrating lasting benefits. 🔵 Safety Profile: Favorably maintained with no severe treatment-related events, ensuring patient safety. 🔬 Immatics commitment to innovation is also underscored by the plans to initiate a Phase 2/3 trial later this year, setting the stage for accelerated approval paths and further clinical success. 🛣️ 📈 Additionally, Immatics financial health is robust, with a cash reserve of $609.7 million ensuring operations into 2027, thanks to a successful $201.5 million public offering earlier this year. 📈 Thanks to Harpreet Singh and his whole team for pushing the boundaries of medical science and improving the lives of those battling cancer. Here’s to making more remarkable progress in 2024! 🎉 Harpreet Singh, Alec Rauschenbusch, Jochen Klueppel, Dr. Benedikt Battke #Immatics #CancerResearch #InnovationInHealthcare #Biotechnology #ACTengine #InvestInHealth
Today we reported our Q1 2024 financial results and provided a clinical data update from our ongoing Phase 1 clinical trial with lead cell therapy candidate, ACTengine® IMA203. Swipe through the graphic below for key updates and takeaways from the last quarter. Click here for the full announcement: https://lnkd.in/d4J3nKy3 #FinancialResults #CellTherapy #Bispecifics #Tcells #Biotech
Leadership with Clarity, Compassion and Determination! Congrats Harpreet Singh
Chief Executive Officer at Immatics
4moThank you, dear Grazia Team, for your relentless support and conviction from day 1! We are on a great track for cancer patients.